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Background
Interleukin (IL)-7 signaling is essential to CD8 T-cell
development, homeostasis and function, and we have
previously shown decreased expression of the IL-7
receptor alpha-chain (CD127) on CD8 T-cells in HIV+
patients. We have also shown that this down regulation
of CD127 is mediated in part by soluble HIV Tat pro-
tein. By removing the IL-7 receptor from the cell sur-
face, Tat is able to inhibit IL-7 signaling and impair
both CD8 T-cell proliferation and cytolytic capacity.
Purpose of the study
To determine the molecular mechanism by which Tat
down regulates CD127.
Methods
Histidine-tagged mutant Tat proteins were generated by
sequentially deleting each of Tat’s six domains and puri-
fying the proteins over Nickel columns. CD8 T-cells
were isolated from healthy HIV-negative volunteers and
incubated in media alone or with purified Tat protein.
CD127 surface and intracellular expression were mea-
sured by flow cytometry, fluorescence microscopy and
by Western blot.
Summary of results
Soluble Tat protein is taken up from the medium by
CD8 T-cells via endocytosis. Once inside the cell, Tat
exits the endosomes during their normal acidification,
enters the cytosol, and then translocates to the inner
leaflet of the cell membrane where it binds directly to
the cytoplasmic tail of CD127. Tat then induces
receptor aggregation and internalization through a pro-
cess dependent on microtubules and directs CD127 to
the proteasome for degradation. While the basic domain
of Tat is required for entry into the cell, the N-terminal
domain of Tat plays a key role in removing CD127 from
the cell membrane. Anti-Tat antibodies, heparin, and
colchicine all block Tat’s ability to down regulate
CD127 on the cell surface.
Conclusions
Given the important role of IL-7 in CD8 T-cell function,
down regulation of the IL-7 receptor alpha-chain by Tat
likely contributes to the impaired cell mediated immu-
nity and inefficient immunologic control of viral replica-
tion evident in HIV+ patients with progressive disease.
This makes Tat an attractive target for the development
of new therapeutics and vaccines. Drugs designed to dis-
rupt the interaction between Tat and CD127, or neutra-
lizing anti-Tat antibodies induced by vaccination could
restore CD127 expression and thus preserve CD8 T-cell
function.
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